S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:ERYP

ERYTECH Pharma Competitors

$8.90
-0.06 (-0.67 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.49
Now: $8.90
$8.90
50-Day Range
$8.60
MA: $10.12
$12.28
52-Week Range
$3.50
Now: $8.90
$13.95
Volume1,175 shs
Average Volume35,818 shs
Market Capitalization$178.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.73

Competitors

ERYTECH Pharma (NASDAQ:ERYP) Vs. VXRT, ORTX, ATHA, TARS, AGEN, and DTIL

Should you be buying ERYP stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to ERYTECH Pharma, including Vaxart (VXRT), Orchard Therapeutics (ORTX), Athira Pharma (ATHA), Tarsus Pharmaceuticals (TARS), Agenus (AGEN), and Precision BioSciences (DTIL).

ERYTECH Pharma (NASDAQ:ERYP) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Profitability

This table compares ERYTECH Pharma and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ERYTECH PharmaN/AN/AN/A
Vaxart-281.50%-84.90%-44.67%

Earnings and Valuation

This table compares ERYTECH Pharma and Vaxart's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ERYTECH PharmaN/AN/A$-70,180,000.00($3.92)-2.27
Vaxart$9.86 million70.71$-18,650,000.00($0.86)-6.88

Vaxart has higher revenue and earnings than ERYTECH Pharma. Vaxart is trading at a lower price-to-earnings ratio than ERYTECH Pharma, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

ERYTECH Pharma has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ERYTECH Pharma and Vaxart, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ERYTECH Pharma0000N/A
Vaxart00203.00

Vaxart has a consensus target price of $15.00, indicating a potential upside of 153.38%. Given Vaxart's higher possible upside, analysts clearly believe Vaxart is more favorable than ERYTECH Pharma.

Insider and Institutional Ownership

6.5% of ERYTECH Pharma shares are owned by institutional investors. Comparatively, 17.9% of Vaxart shares are owned by institutional investors. 7.3% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vaxart beats ERYTECH Pharma on 7 of the 12 factors compared between the two stocks.

Orchard Therapeutics (NASDAQ:ORTX) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Risk & Volatility

Orchard Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.73, meaning that its stock price is 173% more volatile than the S&P 500.

Institutional and Insider Ownership

66.6% of Orchard Therapeutics shares are owned by institutional investors. Comparatively, 6.5% of ERYTECH Pharma shares are owned by institutional investors. 4.2% of Orchard Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Orchard Therapeutics and ERYTECH Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orchard Therapeutics$2.51 million265.83$-163,420,000.00($1.75)-3.92
ERYTECH PharmaN/AN/A$-70,180,000.00($3.92)-2.27

ERYTECH Pharma has lower revenue, but higher earnings than Orchard Therapeutics. Orchard Therapeutics is trading at a lower price-to-earnings ratio than ERYTECH Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Orchard Therapeutics and ERYTECH Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Orchard Therapeutics00403.00
ERYTECH Pharma0000N/A

Orchard Therapeutics presently has a consensus target price of $14.75, indicating a potential upside of 115.01%. Given Orchard Therapeutics' higher possible upside, analysts plainly believe Orchard Therapeutics is more favorable than ERYTECH Pharma.

Profitability

This table compares Orchard Therapeutics and ERYTECH Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Orchard TherapeuticsN/A-65.65%-47.92%
ERYTECH PharmaN/AN/AN/A

Summary

Orchard Therapeutics beats ERYTECH Pharma on 6 of the 11 factors compared between the two stocks.

ERYTECH Pharma (NASDAQ:ERYP) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Institutional & Insider Ownership

6.5% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 66.7% of Athira Pharma shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for ERYTECH Pharma and Athira Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ERYTECH Pharma0000N/A
Athira Pharma00403.00

Athira Pharma has a consensus target price of $42.50, suggesting a potential upside of 120.32%. Given Athira Pharma's higher probable upside, analysts clearly believe Athira Pharma is more favorable than ERYTECH Pharma.

Valuation and Earnings

This table compares ERYTECH Pharma and Athira Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ERYTECH PharmaN/AN/A$-70,180,000.00($3.92)-2.27
Athira PharmaN/AN/A$-5,160,000.00N/AN/A

Profitability

This table compares ERYTECH Pharma and Athira Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ERYTECH PharmaN/AN/AN/A
Athira PharmaN/AN/AN/A

Summary

Athira Pharma beats ERYTECH Pharma on 4 of the 4 factors compared between the two stocks.

Tarsus Pharmaceuticals (NASDAQ:TARS) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Tarsus Pharmaceuticals and ERYTECH Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tarsus Pharmaceuticals00413.20
ERYTECH Pharma0000N/A

Tarsus Pharmaceuticals currently has a consensus target price of $37.25, indicating a potential upside of 21.69%. Given Tarsus Pharmaceuticals' higher possible upside, equities analysts clearly believe Tarsus Pharmaceuticals is more favorable than ERYTECH Pharma.

Valuation and Earnings

This table compares Tarsus Pharmaceuticals and ERYTECH Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus PharmaceuticalsN/AN/AN/AN/AN/A
ERYTECH PharmaN/AN/A$-70,180,000.00($3.92)-2.27

Profitability

This table compares Tarsus Pharmaceuticals and ERYTECH Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tarsus PharmaceuticalsN/AN/AN/A
ERYTECH PharmaN/AN/AN/A

Institutional and Insider Ownership

6.5% of ERYTECH Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats ERYTECH Pharma on 3 of the 4 factors compared between the two stocks.

Agenus (NASDAQ:AGEN) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Earnings & Valuation

This table compares Agenus and ERYTECH Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agenus$150.05 million4.00$-107,660,000.00($0.80)-3.95
ERYTECH PharmaN/AN/A$-70,180,000.00($3.92)-2.27

ERYTECH Pharma has lower revenue, but higher earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than ERYTECH Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Agenus has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.73, suggesting that its stock price is 173% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Agenus and ERYTECH Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agenus00303.00
ERYTECH Pharma0000N/A

Agenus currently has a consensus price target of $8.00, indicating a potential upside of 153.16%. Given Agenus' higher probable upside, research analysts plainly believe Agenus is more favorable than ERYTECH Pharma.

Profitability

This table compares Agenus and ERYTECH Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agenus-192.56%N/A-97.02%
ERYTECH PharmaN/AN/AN/A

Insider and Institutional Ownership

53.4% of Agenus shares are owned by institutional investors. Comparatively, 6.5% of ERYTECH Pharma shares are owned by institutional investors. 4.7% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Agenus beats ERYTECH Pharma on 6 of the 11 factors compared between the two stocks.

ERYTECH Pharma (NASDAQ:ERYP) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares ERYTECH Pharma and Precision BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ERYTECH PharmaN/AN/AN/A
Precision BioSciences-484.81%-105.74%-53.08%

Valuation and Earnings

This table compares ERYTECH Pharma and Precision BioSciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ERYTECH PharmaN/AN/A$-70,180,000.00($3.92)-2.27
Precision BioSciences$22.24 million26.00$-92,880,000.00($1.91)-5.77

ERYTECH Pharma has higher earnings, but lower revenue than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than ERYTECH Pharma, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

6.5% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 48.6% of Precision BioSciences shares are held by institutional investors. 14.3% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for ERYTECH Pharma and Precision BioSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ERYTECH Pharma0000N/A
Precision BioSciences02402.67

Precision BioSciences has a consensus target price of $20.00, suggesting a potential upside of 81.49%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than ERYTECH Pharma.

Volatility and Risk

ERYTECH Pharma has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500.


ERYTECH Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30-2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
News Coverage
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24-8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.18-9.6%$270.20 million$4.13 million-4.84News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.39-11.3%$249.93 millionN/A-7.58
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.84-6.8%$249.20 millionN/A-4.90Analyst Report
News Coverage
Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$5.06-7.1%$215.85 million$2.45 million-2.38Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.23-5.4%$210.84 million$29.35 million-2.59Upcoming Earnings
News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$5.58-0.7%$210.11 million$104.39 million-3.40
Axcella Health logo
AXLA
Axcella Health
1.6$5.51-3.1%$206.85 millionN/A-2.56
INmune Bio logo
INMB
INmune Bio
1.5$15.37-22.5%$206.70 millionN/A-15.85Earnings Announcement
News Coverage
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.43-6.3%$204.18 millionN/A-5.90Upcoming Earnings
Increase in Short Interest
Gap Up
Genfit logo
GNFT
Genfit
1.3$4.87-2.7%$189.24 million$45.88 million-2.47
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$7.18-6.7%$186.70 millionN/A-8.76Gap Up
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.4$4.23-14.2%$178.75 million$1.45 million-1.48Earnings Announcement
Analyst Upgrade
Increase in Short Interest
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$5.35-4.3%$168.68 million$20,000.000.00Decrease in Short Interest
Gap Down
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.5$13.01-19.3%$166.26 million$2.33 million0.00Upcoming Earnings
Gap Up
Champions Oncology logo
CSBR
Champions Oncology
1.1$11.70-0.9%$156.42 million$32.12 million-90.00Upcoming Earnings
News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$13.75-16.7%$154.17 millionN/A0.00High Trading Volume
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$14.65-2.2%$149.81 millionN/A0.00Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.18-6.1%$149.52 millionN/A-2.87Earnings Announcement
News Coverage
Gap Up
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.